Our review included one study by Hafer’s group 30 that showed no statistical benefit with use of prebiotic lactulose but did showed a trend toward clinical benefit.
← all excerpts
Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease.
2
—
—
The sentences
Tursi et al 40 observed that 47.7% of patients treated with VSL#3 were in remission compared to 32.4% in the placebo group; however this did not reach statistical significance.